These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23061676)

  • 1. Immunomodulatory effects of histone deacetylase inhibitors.
    Licciardi PV; Ververis K; Tang ML; El-Osta A; Karagiannis TC
    Curr Mol Med; 2013 May; 13(4):640-7. PubMed ID: 23061676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of natural and synthetic histone deacetylase inhibitors on chromatin.
    Licciardi PV; Kwa FA; Ververis K; Di Costanzo N; Balcerczyk A; Tang ML; El-Osta A; Karagiannis TC
    Antioxid Redox Signal; 2012 Jul; 17(2):340-54. PubMed ID: 22229817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
    Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
    Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.
    Peart MJ; Smyth GK; van Laar RK; Bowtell DD; Richon VM; Marks PA; Holloway AJ; Johnstone RW
    Proc Natl Acad Sci U S A; 2005 Mar; 102(10):3697-702. PubMed ID: 15738394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
    Jazirehi AR
    Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
    Lee JH; Choy ML; Ngo L; Foster SS; Marks PA
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14639-44. PubMed ID: 20679231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.
    Beliakova-Bethell N; Mukim A; White CH; Deshmukh S; Abewe H; Richman DD; Spina CA
    J Biol Chem; 2019 Apr; 294(14):5576-5589. PubMed ID: 30745362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
    Thaler F
    Pharm Pat Anal; 2012 Mar; 1(1):75-90. PubMed ID: 24236715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
    Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
    Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin.
    Newbold A; Lindemann RK; Cluse LA; Whitecross KF; Dear AE; Johnstone RW
    Mol Cancer Ther; 2008 May; 7(5):1066-79. PubMed ID: 18483296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity.
    Rajak H; Singh A; Raghuwanshi K; Kumar R; Dewangan PK; Veerasamy R; Sharma PC; Dixit A; Mishra P
    Curr Med Chem; 2014; 21(23):2642-64. PubMed ID: 23895688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
    Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
    Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses.
    Bolden JE; Shi W; Jankowski K; Kan CY; Cluse L; Martin BP; MacKenzie KL; Smyth GK; Johnstone RW
    Cell Death Dis; 2013 Feb; 4(2):e519. PubMed ID: 23449455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic modulation of gene expression of human leukemia cell lines - induction of cell death and senescence.
    Elknerova K; Myslivcova D; Lacinova Z; Marinov I; Uherkova L; Stöckbauer P
    Neoplasma; 2011; 58(1):35-44. PubMed ID: 21067264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.